JIANGSU

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Tuesday, February 27, 2024
SAN, Conference

SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.

Key Points: 
  • SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida.
  • Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody® ADG126, including key milestones for 2024.
  • Company management will also host investor meetings.

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Retrieved on: 
Friday, February 9, 2024
SAN, CRC, FDA, Part, MSS, Safety, Colorectal cancer, Pembrolizumab, Merck, Patient, CDE, Merck & Co., Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Key Points: 
  • Given the safety profile of ADG126, Adagene has also initiated evaluation of 20 mg/kg loading doses in combination with pembrolizumab in patients with advanced/metastatic cancer.
  • The company plans dose expansion with this regimen in patients with MSS CRC in the US and Asia Pacific.
  • Adagene has also received clearance from the CDE in China to initiate clinical evaluation of ADG126 in combination with pembrolizumab.
  • Data from the ongoing phase 1b/2 clinical trial of ADG126 in combination with pembrolizumab, including dose expansion cohorts, are anticipated throughout 2024:
    Evaluation of 20 mg/kg loading doses for Project Optimus requirements:

Ostin Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Retrieved on: 
Wednesday, January 24, 2024
OST, Disclosure, Calendar

Nanjing, China, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company had received a written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2024, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • Nanjing, China, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company had received a written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2024, indicating that for the last 30 consecutive business days, the closing bid price for the Company’s ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2).
  • This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
  • The Nasdaq notification letter has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market, which will continue to trade uninterrupted on Nasdaq under the ticker "OST".
  • The Nasdaq notification letter will have no effect on the Company’s business operations, and the Company will take all reasonable measures to regain compliance.

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Retrieved on: 
Tuesday, January 16, 2024
Endometrial cancer, Patient, Therapy, Associate, MD, City, MSS, SAN, Liver disease, ASCO, Merck & Co., Poster, Stage 2, Clinical research, Society, Research fellow, Immunotherapy, FACP, Cervical cancer, PRS, PFS, Safety, Liver, Observation, CRC, Pembrolizumab, NCCC, Merck, Physician, Oncology, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Key Points: 
  • “These promising data support further evaluation of this potential best-in-class anti-CTLA-4 antibody, ADG126, in combination with pembrolizumab for MSS CRC patients, including battling new liver lesions in those patients initially without detectable liver metastasis.
  • One of the patients had PD-1 refractory cervical cancer and the other had endometrial cancer.
  • The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level.
  • The clinical profile of ADG126 in combination with pembrolizumab presents a great opportunity for MSS CRC patients that otherwise have limited immunotherapy options available.”

Ostin Technology Group Announces Participation at CES 2024, the Premier Global Technology Trade Show

Retrieved on: 
Thursday, January 4, 2024
Tao, Central Hall, Consumer electronics, Heart rate, Research, Health, Feedback, Electronics, Las Vegas Convention Center, Growth, CES, M4, Retail

The Company’s CES 2024 booth is at 23030, Central Hall in Las Vegas Convention Center.

Key Points: 
  • The Company’s CES 2024 booth is at 23030, Central Hall in Las Vegas Convention Center.
  • As a company committed to pushing the boundaries of technology and driving industry advancements, the Company values the opportunities that CES 2024 will provide.
  • Visitors are welcomed to try out the products to personally experience the unique design, advanced technology, and practicality of the products.
  • Their advanced health tracking features provide real-time monitoring of users' heart rate, sleep quality, physical activity, and more.

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

Retrieved on: 
Thursday, January 4, 2024
Immunotherapy, CRC, ASCO, MSS, SAN, Society, Publication, Poster, Interim, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

Key Points: 
  • - Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -
    SAN DIEGO and SUZHOU, China, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.
  • Details for the poster include:
    The presentation is embargoed until 5:00 p.m. Eastern Time on January 16 and will subsequently be made available on the Publications page of the company’s website here .
  • * As of this press release, muzastotug is used as the non-proprietary name for ADG126.

HKTDC Hong Kong International Optical Fair opens today

Retrieved on: 
Wednesday, November 8, 2023
Certificate, Convention center, Smartglasses, Award, Networking hardware, COVID, Innovation, Attention, CPD, HKTDC, Artificial intelligence, Hospital Authority, Contact lens, Speech, Exhibition, Creativity, HKCEC, ChatGPT, HK, Communication, Gold, Lens, City, Sport, VOY, Social media, Public affairs, Equipment

HONG KONG, Nov 8, 2023 - (ACN Newswire) - Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Optical Manufacturers Association (HKOMA), the 31st edition of the HKTDC Hong Kong International Optical Fair returns, bringing together 700 exhibitors from 11 countries and regions.

Key Points: 
  • HONG KONG, Nov 8, 2023 - (ACN Newswire) - Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Optical Manufacturers Association (HKOMA), the 31st edition of the HKTDC Hong Kong International Optical Fair returns, bringing together 700 exhibitors from 11 countries and regions.
  • The 31st edition of the HKTDC Hong Kong International Optical Fair opened today.
  • HKTDC Deputy Executive Director Sophia Chong said: "The Hong Kong International Optical Fair has always been committed to providing a multi-faceted, one-stop sourcing platform for exhibitors and buyers and the HKTDC expected the industry to create business opportunities through both the physical exhibition and online platform."
  • The Hong Kong International Optical Fair has always been committed to providing a multi-faceted, one-stop sourcing platform for exhibitors and buyers and the HKTDC expected the industry to create business opportunities through both the physical exhibition and online platform.

Full Truck Alliance presents its vision for low emissions shipping at COP 28

Retrieved on: 
Thursday, November 30, 2023
FTA, China Everbright Bank, Partnership, YMM, Government, City, COP, Speech, Climate change, Carbon, CO2, Pressure, Renewable energy

Dubai, Nov. 30, 2023 (GLOBE NEWSWIRE) -- As COP 28 seeks to get commitments from countries and industries to drastically reduce emissions across all sectors, Full Truck Alliance (FTA) showcased its strategy for a greener, technology-driven trucking sector with lower emissions.

Key Points: 
  • Dubai, Nov. 30, 2023 (GLOBE NEWSWIRE) -- As COP 28 seeks to get commitments from countries and industries to drastically reduce emissions across all sectors, Full Truck Alliance (FTA) showcased its strategy for a greener, technology-driven trucking sector with lower emissions.
  • The transportation sector accounts for about a quarter of global greenhouse gas emissions.
  • The combination of planes, trucks, trains, and ocean vessels that drive global shipping are all nearly completely reliant on fossil fuels.
  • Businesses and consumers must take initiative as well, and FTA is ready to do just that in the trucking sector.”

Ostin Technology Group Announces Major Product Upgrade to Pintura Photo Sharing Product

Retrieved on: 
Thursday, November 30, 2023
Tao, Freedom, Research, CES, Wi-Fi, Creativity, Consumer Electronics Show, Online shopping

Nanjing, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces new upgrade to its photo sharing product, Pintura.

Key Points: 
  • Nanjing, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces new upgrade to its photo sharing product, Pintura.
  • Pintura product has recently undergone a remarkable and elegant transformation, unveiling a sleek new round-corner product design.
  • In addition to its aesthetic upgrade, the new model is noticeably lighter than its predecessor, dropping from 4.6kg to 3.5kg.
  • The new Pintura product will push the boundaries of traditional digital displays by encouraging boundless personalization and dynamic self-expression.

Global Times: Amity between people holds key to sound China-US relations: expert

Retrieved on: 
Tuesday, November 28, 2023
Amity, CPAFFC, Policy, Flying Tigers, Hope, Society, Ageing, Shoulder, Culture, Foreign, Music, City, Aircraft, Social media, Conference, Veteran, Philadelphia Orchestra, Interview, Water, Real-time, Multilateralism, Global Times, Non-governmental organization, Tourism, Film industry, Tiger

"Amity between the people holds the key to sound state-to-state relations.

Key Points: 
  • "Amity between the people holds the key to sound state-to-state relations.
  • It has established friendly cooperation relationship with about 400 NGOs and institutions in more than 150 countries.
  • To deepen the exchanges between the peoples of China and the US, the CPAFFC has taken the initiative to proactively facilitate various events.
  • The CPAFFC invited the Flying Tigers to return to China after 80 years for a 10-day visit in early November.